|Event Date/Time: Jan 31, 2011||End Date/Time: Feb 01, 2011|
It is now clear that the use of Biomarkers is an integral part in the future of medicine. With rising development costs and a declining rate of new drug discovery, pharmaceutical companies are now incorporating Biomarker strategies into all new R&D processes.
Key areas that will be addressed are: Bioinformatics, Preclinical Biomarker R&D, Translational Biomarkers, and Personalised Medicine.
Our exceptional speaker line-up includes:
â€¢ Hans Winkler, Senior Director and Global Head, Oncology Biomarkers, Johnson & Johnson
â€¢ Mark Fidock, Associate Research Fellow, Head of Quantitative Biomarkers, Pfizer
â€¢ Huseyin Mehmet, Director of Exploratory Biomarkers, Diabetes, Merck
â€¢ Fernando Ulloa-Montoya, Head of Molecular Biology Technology Group, GlaxoSmithKline
â€¢ Ziad Taib, Statistical Science Director, Astrazeneca
â€¢ Karen Asin, Director, Translational Pharmacology, Takeda
â€¢ Andrew Payne, Senior Group Leader, Cellular Sciences, UCB
â€¢ Ge Ruigt, Director Experimental Medicine Neuroscience, Merck
And much more....